Tapering medication for paroxetine shortly available

20 October 2013


Twenty two prominent Dutch psychiatrists recommend the use of specially designed tapering medication for the cessation of treatment with paroxetine and venlafaxine. In the Dutch professional journal Tijdschrift voor Psychiatrie P. Groot et al.*) explain why the tapering of these antidepressants should be much more gradual than is currently possible with the registered commercial preparations.

At present, many patients suffer from discontinuation symptoms upon stopping the treatment. Apart from the inconvenience, some patients take resort in resuming the treatment to get rid of the symptoms. The problem is that the lowest dosages on the market are much too high for use in a safe tapering regimen.

There is abundant evidence from the medical literature that the incidence and the severity of discontinuation symptoms decreases when the daily doses are lowered by very small decrements over a period of several weeks, especially in the final stages of tapering.
In addition, the risk of recurrence of the depression is lower.

With the assistance of many experts, Cinderella has succeeded in getting consensus on a tapering schedule for paroxetine that meets these requirements and in having the appropriate formulations manufactured by Paul Harder, pharmacist in Bavel near Breda.

Two different tapering strips will be made available:

1. Tapering strip PRXT-20-28 to lower the daily dose of paroxetine from 20 mgover 28 days to zero.

2. Tapering strip PRXT-10-21 to lower the daily dose of paroxetine from 10 mgover 21 days to zero.

It is expected that the strips will ready for delivery in January. A prescription from the patients’ physician is required. Instructions how to order will be published on this site. www.cinderella-tx.org/tapering.

Cinderella will proceed with the development of similar tapering strips for Venlafaxine and other drugs.
*) English translation:  Tapering. Taperingstrips for paroxetine and velafaxine

Leave a reply


Cinderella is interested in compounds showing promise in preclinical research and phase-1 studies.
The efficacy and therapeutic ratio of these drugs will be demonstrated or disproved in a short period of time and in a small number of patients.